Bruker Corporation is a manufacturer of analytical and medical instruments, for use in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.
Bruker has released the B.I.QUANT-PS™ automated metabolite quantification solution for use with the company’s AVANCE IVDr™ 600 MHz NMR platform, which brings cost-effective nuclear magnetic resonance (NMR) screening to high-throughput, translational phenomics research and biobank metabolic analysis.
The novel B.I.QUANT-PS™ delivers automatic quantification of 26 disease-relevant metabolites and in the same experiment and also enables lipoprotein subclass analysis. In addition, the NMR reference spectral base for pure compounds in biofluids, BBIOREFCODE, has been expanded to cover 800 compounds and >23.500 high quality NMR spectra. B.I.QUANT-PS™ is a components of the B.I.BioBankTool™.
B.I.BioBankTool™ is a solution for biobank standardization and quality control (QC). The B.I.BioBankTool QC procedure delivers information on pre-analytics, sample preparation and analytical performance. It gives information on matrix identity and integrity, e.g. for urine, EDTA-plasma, citrate plasma or serum, and it can flag sample degradation.
It also confirms whether the biobank donor was fasting or non-fasting, identifies contaminations, as well as reported or unreported medications. The B.I.BioBankTool can generate quantitative information on 150 metabolites in urine, and greater than 140 lipoprotein and small molecule parameters in plasma or serum. Retrospective analysis of previously recorded data is feasible.
“We are excited about the possibilities of NMR screening in biobank quality control to deliver standardized analytical data for biobank metadata. Having multiple biobanks on the same NMR standards will create a wealth of data from all over the world for integration in support of the development of efficient epidemiological and diagnostic tools.” – Professor Matthias Nauck, Director of the Institute for Clinical and Laboratory Medicine at Medical University of Greifswald.
Source:
